EX-23.1 3 limn-20260331xex23d1.htm EX-23.1

Exhibit 23.1

​

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

​

We hereby consent to the use in the Prospectus constituting a part of this Registration Statement on Form S-1 of our report dated March 31, 2026 (which includes an explanatory paragraph relating to Liminatus Pharma, Inc.’s ability to continue as a going concern) relating to the consolidated financial statements of Liminatus Pharma, Inc. as of and for the years ended December 31, 2025 and 2024, which is contained in the Prospectus.

​

We also consent to the reference to our Firm under the heading “Experts” in the Prospectus.

​

/s/ WithumSmith+Brown, PC

​

Whippany, New Jersey

June 23, 2026